What The Article Says: This Viewpoint proposes ways to maximize vaccine efficacy and allocation given the rise of coronavirus variants and authorization of a Johnson & Johnson vaccine, including reserving the latter for younger healthier populations, boosting it with a single-dose messenger RNA (mRNA) vaccination and single mRNA immunization of people with prior documented SARS-CoV-2 infection.
Authors: John P. Moore, Ph.D., of Weill Cornell Medicine in New York, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2021.3465)
Editor's Note: The article includes an Editor's Note. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory: The full article is linked to this news release. A livestream with the author also is scheduled for Thursday at 3:50 P.M. (ET) and will be available here: http://ja.ma/moore0304
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.3465?guestAccessKey=a44d6501-b605-47f2-970e-f8cc12936363&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=030421
JAMA